Claims 1-24 (cancelled)

25. (currently amended) A controlled release oral dosage form for once-a-day administration of a therapeutic agent comprising:

a. [A]a core which comprises:

i. a low solubility therapeutic agent wherein the therapeutic agent is topiramate;

ii. a structural polymer;

iii. a solubilizing surfactant;

b. a semipermeable membrane surrounding the core; and

c. an exit orifice through the semipermeable membrane which communicates with the core so as to allow release of the therapeutic agent as a solution or suspension to the environment;

[i.] wherein the dosage form releases the therapeutic agent over a prolonged period of time.

26. (original) The controlled release oral dosage form of Claim 25 adapted to release the therapeutic agent at a substantially zero order release rate.

27. (original) The controlled release oral dosage form of Claim 25 adapted to release the therapeutic agent at a substantially ascending release rate.

28. (original) A method for delivering high doses of low solubility therapeutic agents comprising orally administering the dosage form of Claim 25 to a subject.

29. (original) A method for enhancing the bioavailability

of a therapeutic agent comprising orally administering the dosage form of Claim 25 to a subject.

30. (previously presented) The dosage form of Claim 25, which is adapted to release a high dose of the therapeutic agent.

31. (previously presented) The dosage form of Claim 30 wherein the high dose of the therapeutic agent is between about 20% and about 90% by weight of the therapeutic composition.

32. (previously presented) The dosage form of Claim 31 wherein the high dose of the therapeutic agent is between about 30% and about 40% by weight of the therapeutic composition.

33. (previously presented) The dosage form of Claim 25 wherein the high dose of therapeutic agent is between about 1 μg and 750 mg of the therapeutic agent.

34. (previously presented) The dosage form of Claim 33 wherein the high dose of therapeutic agent is between about 10 mg and about 250 mg of the therapeutic agent.

35. (previously presented) The dosage form of Claim 34 wherein the high dose of therapeutic agent is between about 25 mg and about 400 mg of the therapeutic agent.

Claims 36 and 37(cancelled)

38. (previously presented) The dosage form of Claim 25 wherein the amount of structural polymer is between about 1% and 80% by weight of the composition.

39. (previously presented) The dosage form of Claim 38 wherein the amount of structural polymer is between about 5% and 50% by weight of the composition.

40. (previously presented) The dosage form of Claim 39 wherein the amount of structural polymer is between about 5% and 15% by weight of the composition.

41. (previously presented) The dosage form of Claim 25 wherein the structural polymer is polyethylene oxide of about 100,000 to 200,000 molecular weight.

42. (previously presented) The dosage form of Claim 25 wherein the solubilizing surfactant is selected from the group consisting of polyoxyl 40 stearate, polyoxyl 50 stearate, poloxamers, and a:b:a triblock copolymers of ethylene oxide:propylene oxide:ethylene oxide.

43. (previously presented) The dosage form of Claim 25 wherein the amount of solubilizing surfactant is between about 5% and 50% by weight of the composition.

44. (previously presented) The dosage form of Claim 43 wherein the amount of solubilizing surfactant is between about 5% and 40% by weight of the composition.

Claim 45 (canceled)

46. (previously presented) The dosage form of Claim 45 wherein the structural polymer is polyethylene oxide of about 100,000 to 200,000 molecular weight, and the solubilizing surfactant is poloxamer 407.